#### **CURRICULUM VITAE**

#### **Personal Data:**

Telephone: 816-235-1624 cell 913-424-0853

e-mail johnstont@umkc.edu

#### **Education**:

1987-1988 Post-Doctoral Research Fellow; Joint appointment in the Departments of Pediatric

Cardiology (The University of Michigan Medical School) & Pharmaceutics (The

University of Michigan College of Pharmacy)

1987 Ph.D.; Department of Pharmaceutics, College of Pharmacy, University of Minnesota,

Minneapolis, Minnesota 55455

1980 B.S.; College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455

## **Professional Experience:**

2008 – Present Professor of Pharmaceutics, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City

1995 – 2008 Associate Professor of Pharmaceutics, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City

1988 – 1994 Assistant Professor of Pharmaceutics / Pharmacokinetics, Department of Pharmaceutics and Pharmacodynamics, College of Pharmacy, University of Illinois, Chicago, IL

#### **Licensure**:

Licensed to practice pharmacy in the state of Minnesota-License number = 113584-8 Licensed to practice pharmacy in the state of Kansas-License number = 13242



#### **Awards and Citations:**

March 2008	Rho Cho Pharmacy Honor Society Faculty Member of the Year, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO
Nov 2007	Outstanding Teacher of the Year, School of Pharmacy, University of Missouri- Kansas City, Kansas City, MO
July 2002	Designated as a "Master Instructor" in the field of pharmaceutics by the American Association of Colleges of Pharmacy, Kansas City, MO
July 1994	Cited as an Outstanding Pharmaceutical Educator in the U.S. at the meeting of the American Association of Colleges of Pharmacy, Albuquerque, NM.
May 1994	Outstanding Teacher of the Year, College of Pharmacy, University of Illinois, Chicago, IL 60612
May 1990	Outstanding Teacher of the Year, College of Pharmacy, University of Illinois, Chicago, IL 60612
May 1988	Received the American Society for Artificial Internal Organs Travel Fellowship Award for the Society's 34 <sup>th</sup> Annual Meeting in Reno, Nevada
August 1987	Article by Ms. Kristin Jenkins entitled "Implantable Delivery Systems Revolutionizing How We Take Drugs", The Medical Post (The Maclean Hunter Newspaper for the Canadian Medical Profession), Volume 23, No. 29.
August 1987	Article by Ms. Pamela Harrison entitled "Bioprosthetic Heart Valves Being Saved by Novel Drug Delivery System", Ontario Medicine (a newspaper for Ontario's Medical Profession), Volume 6, No. 16
1983-1984	Theodore J. Rowell Fellowship, University of Minnesota, Minneapolis, Minnesota 55455
1981	Rho Chi Honor Society Award, University of Minnesota, Minneapolis, Minnesota 55455
1980	Rho Chi Research Award, University of Minnesota, Minneapolis, Minnesota 55455

### **Current and/or Past Professional and Honorary Memberships**:

American Association of Pharmaceutical Scientists (AAPS)

American Pharmaceutical Association (APhA)

American Association of Colleges of Pharmacy (AACP)

Minnesota State Pharmaceutical Association (MSPhA)

Kansas Pharmacists Association (KPhA)

Rho Chi Pharmacy Honor Society

Controlled Release Society (CRS)

Parenteral Drug Association (PDA)

Who's Who in the Midwest

Who's Who in the United States

Who's Who in Science and Engineering

Who's Who in Medicine and Healthcare

Who's Who in American Education

Listed in "The International Directory of Distinguished Leadership"

New York Academy of Sciences

Secretary for the Teachers of Pharmaceutics Section of AACP (2002-2004)



#### **Editorial Experience:**

1987 - present **Reviewer** 

Journal of Pharmaceutical Science & Technology

Journal of Pharmaceutical Science

Pharmaceutical Research

International Journal of Pharmaceutics

Journal of Biological Chemistry

Drug Development and Industrial Pharmacy

Atherosclerosis

Pharmaceutical Development and Technology

Journal of Pharmacy and Pharmacology

Molecular Pharmaceutics

European Journal of Pharmaceutics and Biopharmaceutics

## **Editorial Board Member**

2002 – present Journal of Pharmacy and Pharmacology

2007 – present Journal of Ocular Biology, Diseases, and Informatics

### **Grant Review Experience:**

1987 - 1994	Served as a Reviewer for the American Heart Association of Illinois
1995 - 1999	Served as a Reviewer for the American Heart Association-Heartland
	Consortium; formerly the AHA-Kansas Affiliate
2000 procent	Company on an ad has reviewer for the National Institutes of Health (NILL)

2000-present Serve as an *ad hoc* reviewer for the National Institutes of Health (NIH)

#### Teaching, Research, and Administrative Activities:

1988-1994	Served on the College of Pharmacy's Educational Policy Committee (University of Illinois). Was elected by colleagues for three consecutive two-year terms.
1989-2004	Taught a graduate-level course on "Stabilization of Pharmaceutical Systems" with Emphasis on Recombinant Proteins.
1988-2004	Participated in team-taught pharmaceutics classes in the College of Pharmacy's professional Pharm.D. curriculum.
August 1990	Lectures presented to the U.S. Food and Drug Administration on Pharmacokinetics and Stabilization of Pharmaceutical Systems.
June 2000	Lectures presented to U.S. Food and Drug Administration on Dissolution and <i>In Vitro/In Vivo</i> Correlation.



#### **Publications**

- 1. Intentionally left blank
- 2. Intentionally left blank
- 3. Intentionally left blank
- 4. Intentionally left blank
- 5. **T.P. Johnston**, T.A. Korolenko, Restoration of serum lipids and cardiac proteases following an acute challenge of the hyperlipidemic agent, poloxamer 407, in mice. In Preparation, 2014.
- 6. **T.P. Johnston**, P. Koulen. Effects of sustained dyslipidemia on the neurodegeneration of retinal ganglion cells in diabetic retinopathy. In Preparation, 2015.
- 7. T.A. Korolenko, **T.P. Johnston**. Chap. X: Aspartate protease cathepsin D in liver and heart injury, pathophysiology and therapy, In: *Cathepsin D: Molecular Characterization, Pathophysiological Functions, and Health Implications*, J.B. Cohen, L.P. Ryseck (Eds), Nova Science Publishers, Inc., Hauppauge, NY, 2015, Accepted.
- 8. **Johnston, T.P.**, Chap. 1: Anatomy and physiology of the oral mucosa and its relevance to local and systemic oral mucosal drug delivery, In: *Oral Mucosal Drug Delivery and Therapy*, M. Rathbone, S. Senel, I. Pather (Eds), Advances in Delivery Science and Technology Series, Springer, New York, NY, 2014, In Press.
- 9. **T.P. Johnston**, T.A. Korolenko. Chap. 1: Statin treatment in experimental lipemia and atherosclerosis: The similarities and differences with humans, In: *Statins: Medical Uses, Mechanisms of Action, and Clinical Outcomes*, ER Travers (Ed), Nova Science Publishers, Inc., Hauppauge, NY, 2014. ISBN: 978-1-63463-096-2
- 10. V.M. Loginova, T.A. Korolenko, **T.P. Johnston**, F.V. Tuzikov, N.V. Goncharova. Lipoprotein fractions and *sub*fractions and heart proteases during acute lipemia in a murine model of atherosclerosis. Medimond International Proceedings, Vol #:pp.-pp., 2014, In Press.
- 11. T.A. Korolenko, **T.P. Johnston**, E. Pisareva, E. Filjushina, E. Machova. Serum cystatin C and chitotriosidase in acute dyslipidemia: Can they serve as potential early biomarkers for atherosclerosis? *J. Pharmacol. Toxicol.* Submitted, 2014.
- 12. A.D. Vadlapudi, R.K. Vadlapatla, **T.P. Johnston**, A.K. Mitra, *Peptides and Proteins: Buccal Absorption*, In: J. Swarbrick (Eds.), Encyclopedia of Pharmaceutical Science and Technology, 4<sup>th</sup> Edition, Taylor & Francis, NY (2013) pp. 2525-2541.
- 13. T.A. Korolenko, **T.P. Johnston**, N.I. Dubrovina, Y.A. Kisarova, S.Y. Zhanaeva, N.A. Zhukova, Effect of poloxamer 407 administration on the serum lipids profile, anxiety level, and protease activity in the heart and liver of mice, *Interdiscip. Toxicol.* 6(1),18-25, 2013.
- 14. T.A. Korolenko, F.V. Tuzikov **T.P. Johnston**, N.A. Tuzikova, Y.A. Kisarova. The influence of repeated administration of poloxamer 407 on serum lipoproteins and protease activity in mouse liver and heart. *Can. J. Physiol. Pharmacol.* 90, 1456-1468, 2012.
- 15. **T.P. Johnston**, T. Yasuda, M. Shinohara, M. Inoue, T. Ishida. The effect of poloxamer 407 on the functional properties of HDL in mice, *J. Pharm. Pharmacol.*, 64, 677-687, 2012.



- 16. T.A. Korolenko, F.V. Tuzikov, M.S. Cherkanova, **T.P. Johnston**, N.A. Tuzikova. Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with poloxamer 407-induced lipemia. *Can. J. Physiol. Pharmacol*, 90, 141-153, 2012.
- 17. **T.P. Johnston**, P. Mondal, D.J. Pal, S. MacGee, A.J. Stromberg, H. Alur. Canine periodontal disease control using a clindamycin hydrochloride gel. *J. Vet. Dent.*, 28, 224-229, 2011.
- 18. T.A. Korolenko, M.S. Cherkanova, **T.P. Johnston**, E.A. Gashenko, B.I. Yu. Chapter 8: *Cystatin C, Atherosclerosis, and Lipid-lowering Therapy With Statins*, In: Cystatins: Protease Inhibitors, Biomarkers, and Immunomodulators, J.B. Cohen, L.P. Ryseck (Eds), Nova Science Publishers, Inc., Hauppauge, NY, 187-204, 2011. ISBN 978-1-61209-343-7
- 19. H. Alur, P. Mondal, **T.P. Johnston**. Evaluation of TRI-726 as a drug delivery platform. *Drug Develop. Indust. Pharm.*, 37, 995-1001, 2011.
- 20. T.A. Korolenko, M.S. Cherkanova, F.V. Tuzikov, **T.P. Johnston**, N.A. Tuzikova. Influence of atorvastatin on fractional and *sub*fractional composition of serum lipoproteins and MMP activity of mice with Triton WR-1339-induced lipemia, *J. Pharm. Pharmacol.*, 63, 833-839, 2011.
- 21. M.A. Ruby, B. Goldenson, G. Orasanu, **T.P. Johnston**, J. Plutzky, R.M. Krauss. VLDL hydrolysis by LpL activates PPARα through generation of unbound fatty acids, *J. Lipid Res.*, 51, 2275-2281, 2010.
- 22. T.A. Korolenko, F.V. Tuzikov, **T.P. Johnston**, N.A. Tuzikova, E.E. Filjushina, V.M. Loginova, N.G. Savchenko. Influence of poloxamer 407 on fractional and *sub*fractional composition of serum lipoproteins in mice, *HEALTH*, 2, 722-730, 2010.
- 23. **T.P. Johnston**, Poloxamer 407 as a general lipase inhibitor: its implication in lipid metabolism and atheroma formation in C57BL/6 mice, *J. Pharm. Pharmacol.*, 62, 1807-1812, 2010.
- 24. P. Karla, R. Earla, S. Boddu, **T.P. Johnston**, D. Pal, A.K. Mitra. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. *Curr. Eye Res.*, 34, 1-9, 2009.
- 25. X. Zhou, **T.P. Johnston**, D. Johansson, P. Parini, K. Funa, J. Svensson, G.K. Hansson. Hypercholesterolemia leads to elevated TGF-β1 activity and T helper 3-dependent autoimmune responses in atherosclerotic mice. *Atherosclerosis*, 204, 381-387, 2009.
- 26. **T.P. Johnston**, Poloxamer 407 administration to C57BL/6 mice causes an elevation in the soluble adhesion molecules, intercellular adhesion molecule-1 (sICAM-1), vascular cell adhesion molecule-1 (sVCAM-1), and sE-selectin, *J. Pharm. Pharmacol.*, 61, 1681-1688, 2009.
- 27. H. Tanaka, T. Ishida, **T.P. Johnston**, T. Yasuda, T. Ueyama, Y. Kojima, R.K. Kundu, T. Quertermous, Y. Ishikawa, K. Hirata, Role of endothelial lipase in plasma HDL levels in a murine model of hypertriglyceridemia, *J. Atheroscler. Thromb.*, 16, 327-338, 2009.
- **T.P. Johnston**, D.J. Waxman, The induction of atherogenic dyslipidemia in poloxamer 407-treated mice is not mediated through PPARα, *J. Pharm. Pharmacol.*, 60, 753-759, 2008.
- 29. N. Wongsiriroj, R. Piantedosi, K. Palczewski, I.J. Goldberg, **T.P. Johnston**, E. Li, W.S. Blaner. The molecular basis of retinoid absorption: A genetic dissection. *J. Biol. Chem.*, 283, 13510-13519, 2008.
- **T.P. Johnston**, D.J. Waxman, Circulating free fatty acids are increased independently of PPARγ activity after administration of poloxamer 407 to mice, *Can. J. Physiol. Phamacol.*, 86, 643-649, 2008.



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

# **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

